AUPH - Aurinia gains the most in three months on above average volume

The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals (AUPH +10.6%) have added more than a tenth on Wednesday to record the biggest intraday gain in over three months amid rising chatter on social media. Currently, about 3.8 million Aurinia (NASDAQ:AUPH) shares have changed hands compared to 65-day average volume of ~3.7 million. Many have taken to Twitter to talk about a patent dispute between the company and the generic drugmaker Sun Pharmaceuticals. With its latest 10-K filing, Aurinia (AUPH), which markets lupus nephritis therapy Lupkynis in the U.S. and internationally in partnership with Otsuka Pharmaceutical Co., Ltd, disclosed a new petition filed by Sun Pharma last month on a key patent related to Lupkynis.

For further details see:

Aurinia gains the most in three months on above average volume